Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have greatly improved the prognosis and overall management of non-small cell lung cancer (NSCLC) patients, but in the long term less than 20% of patients benefit from treatment with ICIs. Therefore, it is necessary to guide the choice of immunotherapy population through biomarkers in order to maximize the benefit for NSCLC patients. This article mainly explores the relationship between the efficacy of immunotherapy and specific tumor mutation gene characteristics in an NSCLC population.

Methods

This was a prospective analysis of patients with advanced NSCLC who visited the Department of Respiratory Medicine of Peking Union Medical College Hospital from March 2018 to June 2019 and were instructed to use PD-1 inhibitors. The follo

SUBMITTER: Song P 

PROVIDER: S-EPMC7262886 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature